In 2023, Giovanni Caforio earned $2.49M in total compensation at Bristol-Myers Squibb, primarily from $1.75M salary. Most recently acquired 653 shares in May 2024. Currently holds stock worth $28.89M. Has donated $125.15K in stock to charitable causes. Led Bristol-Myers Squibb as CEO for 8 years.
Compensation History
Annual executive compensation data for Giovanni Caforio, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$2.49M
Salary
$1.75M
Bonus
$0.00
Other
$734.61K
Salary
$1.75MBoard Justification
The compensation philosophy emphasizes aligning pay with performance and shareholder interests, focusing on long-term value creation.
Bonus
$0.00Board Justification
No cash bonus was awarded for 2023.
Other Compensation
$734.61KBoard Justification
Includes financial counseling, executive physicals, air travel, and contributions to savings plans.
Restricted Stock
Board Justification
No additional stock awards were granted in 2023; all stock awards were from previous years.
Performance Metrics
Compensation is based on company performance metrics including revenue, operating margin, and total shareholder return.
Giovanni Caforio
Ex-CEO of Bristol-Myers Squibb
Education
Medical degree from the University of Rome
Field of Expertise
Healthcare & Life Sciences - Medicine
Sector of Economy
Healthcare
Born
April 17, 1965 - 60 years ago
CEO of Bristol-Myers Squibb for
8 years 5 months (May 2015 - Nov 2023)
Previous Experience
Various senior roles within Bristol-Myers Squibb
Holdings
Track Giovanni Caforio's stock holdings and portfolio value over time.
Total Stock Sold
$46.74M
$46.74M
720,313 BMY shares
What if they kept their stock?
If Giovanni Caforio didn't sell their stock, today they would have:
Extra BMY720,313 shares worth $37.42M.
This is -19.95% and $9.32M less than what they got when they sold the stock.
Charitable Transactions
2,409 shares
BMY
Recent Charitable Transactions
440 shares
BMY
Oct 10, 2023
Charity
420 shares
BMY
Mar 21, 2022
Charity
525 shares
BMY
Dec 31, 2021
Charity
480 shares
BMY
Dec 31, 2020
Charity
544 shares
BMY
Dec 31, 2019
Charity
Insider Trading
Giovanni Caforio's recent stock transactions, purchases, and sales filed with the SEC.
653 shares
SYK
May 9, 2024
Received
440 shares
BMY
Oct 10, 2023
Charity
705 shares
SYK
May 10, 2023
Received
$17.92M
BMY at $74.65/share
Feb 6, 2023
Sale
$1.74M
BMY at $69.71/share
Sep 20, 2022
Sale
$3.59M
BMY at $71.84/share
Sep 15, 2022
Sale
$2.22M
BMY at $74.04/share
Jun 13, 2022
Sale
420 shares
BMY
Mar 21, 2022
Charity
$1.79M
BMY at $71.52/share
Mar 21, 2022
Sale
$2.01M
BMY at $67.00/share
Feb 24, 2022
Sale
Rivals
Compare Giovanni Caforio with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M